Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
HBV
MCID: HPT016
MIFTS: 70

Hepatitis B (HBV)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hepatitis B

About this section

MalaCards integrated aliases for Hepatitis B:

Name: Hepatitis B 39 12 77 56 44 45 15 74
Hepatitis B Infection 12 15 17
Hepatitis B, Chronic 74
Chronic Hepatitis B 12
Hepatitis B Chronic 56
Serum Hepatitis 12
Hbv 49

Classifications:

MalaCards categories:
Global: Infectious diseases Genetic diseases Rare diseases Cancer diseases
Anatomical: Immune diseases Liver diseases Gastrointestinal diseases Skin diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2043
MeSH 45 D006509
NCIt 51 C3097
SNOMED-CT 69 66071002
Sources

Summaries for Hepatitis B

About this section
MedlinePlus : 44 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis B, is caused by the hepatitis B virus (HBV). Hepatitis B spreads by contact with an infected person's blood, semen, or other body fluid. An infected woman can give hepatitis B to her baby at birth. If you get HBV, you may feel as if you have the flu. You may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. Some people have no symptoms at all. A blood test can tell if you have it. HBV usually gets better on its own after a few months. If it does not get better, it is called chronic HBV, which lasts a lifetime. Chronic HBV can lead to cirrhosis (scarring of the liver), liver failure, or liver cancer. There is a vaccine for HBV. It requires three shots. All babies should get the vaccine, but older children and adults can get it too. If you travel to countries where Hepatitis B is common, you should get the vaccine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis B, also known as hepatitis b infection, is related to hepatitis d and hepatitis, and has symptoms including fever, vomiting and fatigue. An important gene associated with Hepatitis B is LAMTOR5 (Late Endosomal/Lysosomal Adaptor, MAPK And MTOR Activator 5), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Human cytomegalovirus infection. The drugs Guaifenesin and Methadone have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and testes, and related phenotype is neoplasm.

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis B virus, which is transmitted by sexual contact, transmitted by blood transfusions, and transmitted by fomites like needles or syringes. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 77 Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver. It... more...

Sources

Related Diseases for Hepatitis B

About this section

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis B via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 689)
# Related Disease Score Top Affiliating Genes
1 hepatitis d 33.5 F2 GPT IFNA2
2 hepatitis 32.5 AFP F2 GPT IFNA1 IFNA2 IFNAR2
3 liver disease 32.2 AFP ALB F2 GPT IFNA1 TNF
4 hepatitis c 31.7 GPT IFNA1 IFNA2 IFNAR2 IFNG TNF
5 infantile liver failure syndrome 1 31.4 ALB F2 GPT
6 liver cirrhosis 31.2 AFP ALB F2 GPT IFNA1
7 acute liver failure 31.1 ALB F2 GPT
8 human immunodeficiency virus infectious disease 31.1 APOBEC3G IFNA1 IFNG TNF
9 viral hepatitis 31.0 AFP ALB F2 GPT IFNA1 IFNA2
10 mumps 30.9 IFNAR2 IFNG TNF
11 rheumatic disease 30.8 IFNA1 IFNG TNF
12 cryoglobulinemia, familial mixed 30.7 IFNA1 IFNA2
13 measles 30.7 IFNA1 IFNAR2 IFNG
14 hepatitis a 30.7 AFP ALB F2 GPT IFNG TNF
15 schistosomiasis 30.7 ALB F2 IFNG TNF
16 hepatitis e 30.6 ALB F2 GPT IFNG TNF
17 demyelinating disease 30.6 IFNA1 IFNG TNF
18 portal hypertension 30.6 ALB F2 GPT TNF
19 nonalcoholic steatohepatitis 30.5 F2 GPT TNF
20 acquired immunodeficiency syndrome 30.5 ALB IFNA1 IFNA2 IFNG TNF
21 mouth disease 30.4 IFNA1 IFNG TNF
22 severe acute respiratory syndrome 30.4 IFNA1 IFNG TNF
23 chronic graft versus host disease 30.4 ALB IFNG TNF
24 alcoholic liver cirrhosis 30.3 AFP ALB F2
25 hepatic encephalopathy 30.3 ALB F2 GPT TNF
26 biliary atresia 30.3 ALB GPT SLC10A1
27 meningitis 30.2 ALB IFNG MBL2 TNF
28 esophageal varix 30.2 AFP ALB F2
29 hepatic coma 30.2 ALB F2 GPT
30 peritonitis 30.2 ALB F2 TNF
31 non-a-e hepatitis 30.2 ALB F2
32 uveitis 30.2 IFNA2 IFNG TNF
33 systemic lupus erythematosus 30.2 ALB F2 IFNA1 IFNG MBL2 TNF
34 bacterial infectious disease 30.1 IFNG MBL2 TNF
35 cholecystitis 30.1 ALB F2 GPT
36 visceral leishmaniasis 30.1 ALB IFNG TNF
37 hypersplenism 30.1 ALB F2 IFNG
38 cholangitis 30.1 ALB F2 GPT TNF
39 typhoid fever 30.0 ALB F2 IFNG TNF
40 analbuminemia 30.0 ALB F2 GPT
41 aspergillosis 30.0 IFNG MBL2 TNF
42 endocarditis 30.0 ALB F2 TNF
43 gastroenteritis 29.9 ALB IFNA1 TNF
44 alcoholic hepatitis 29.9 ALB F2 GPT TNF
45 fascioliasis 29.9 ALB GPT IFNG
46 mycobacterium tuberculosis 1 29.9 IFNG MBL2 TNF
47 opisthorchiasis 29.9 AFP GPT TNF
48 multiple sclerosis 29.8 IFNA1 IFNG MIR17 TNF
49 kawasaki disease 29.8 ALB MBL2 TNF
50 bilirubin metabolic disorder 29.7 ALB F2 GPT

Graphical network of the top 20 diseases related to Hepatitis B:



Diseases related to Hepatitis B
Sources

Symptoms & Phenotypes for Hepatitis B

About this section

Symptoms:

12
  • • fever
  • • vomiting
  • • fatigue
  • • abdominal pain
  • • jaundice
  • • nausea
  • • joint pain
  • • loss of appetite
  • • clay-colored bowel movements

UMLS symptoms related to Hepatitis B:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis B:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 AFP AIP ALB IFNAR2 IFNG TNF
Sources

Drugs & Therapeutics for Hepatitis B

About this section

Drugs for Hepatitis B (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 538)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 93-14-1 3516
2
Methadone Approved Phase 4,Phase 3,Phase 2,Not Applicable 76-99-3 4095
3
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
4
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 143491-57-0 60877
5
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
6
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21645-51-2
7
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
8
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
9
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
10
Atorvastatin Approved Phase 4 134523-00-5 60823
11
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99210-65-8, 215647-85-1
12
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
13
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
14
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
16
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
17
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
18
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
19
rituximab Approved Phase 4,Phase 2,Phase 3,Not Applicable 174722-31-7 10201696
20
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
21
tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1401-55-4
22 Ethiodized oil Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 8008-53-5
23
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 2713 9552079
24
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492 6473866
25
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
26
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 123774-72-1, 83869-56-1
27
Lenograstim Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 135968-09-1
28
Alprostadil Approved, Investigational Phase 4,Phase 2 745-65-3 149351 5280723
29
glycyrrhizin Approved, Experimental Phase 4,Phase 3,Phase 2 1405-86-3 3495
30
Simethicone Approved Phase 4,Phase 3 8050-81-5
31
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
32
Zidovudine Approved Phase 4,Phase 2,Not Applicable 30516-87-1 35370
33
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
34
leucovorin Approved Phase 4,Phase 1,Phase 2,Not Applicable 58-05-9 6006 143
35
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2 376348-65-1 3002977
36
Ledipasvir Approved Phase 4,Phase 3,Phase 2 1256388-51-8 67505836
37
Sofosbuvir Approved Phase 4,Phase 3,Phase 2,Not Applicable 1190307-88-0 45375808
38
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 1 54-05-7 2719
39
Etanercept Approved, Investigational Phase 4 185243-69-0
40
Adalimumab Approved Phase 4 331731-18-1 16219006
41
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 62-33-9, 60-00-4 6049
42
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
43
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 23925 27284
44
Cobicistat Approved Phase 4,Phase 3,Phase 2 1004316-88-4
45
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
46
Ibuprofen Approved Phase 4 15687-27-1 3672
47
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
48
Etravirine Approved Phase 4 269055-15-4 193962
49
Polyestradiol phosphate Approved Phase 4 28014-46-2
50
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757

Interventional clinical trials:

(show top 50) (show all 1726)
# Name Status NCT ID Phase Drugs
1 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
2 Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients Unknown status NCT02963714 Phase 4
3 Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients Unknown status NCT02991599 Phase 4
4 Immunogenicity of Hepatitis B Vaccination Among Drug Users Unknown status NCT02959775 Phase 4
5 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
6 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
7 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
8 Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation Unknown status NCT02417207 Phase 4 Entecavir combined long-term low-dose HBIG group intramuscular;Entecavir combined HBIG group short-term high-dose intravenous
9 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
10 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
11 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
12 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
13 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
14 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
15 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
16 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
17 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
18 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
19 Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
20 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
21 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
22 Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
23 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
24 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
25 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
26 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
27 Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
28 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
29 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
30 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
31 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
32 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
33 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
34 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
35 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon
36 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4 Entecavir and peginterferon (Pegasys) (52 weeks);Peginterferon (Pegasys) (96 weeks);Peginterferon (Pegasys) (48 weeks)
37 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
38 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
39 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
40 Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude Unknown status NCT02523547 Phase 4 Cavir;Baraclude
41 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
42 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
43 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
44 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
45 Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
46 Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy Unknown status NCT02594293 Phase 4 PegIFN alfa-2a
47 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
48 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
49 Efficacies of Entecavir Add on HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02368288 Phase 4 entecavir
50 Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission Unknown status NCT00939068 Phase 4 Telbivudine

Search NIH Clinical Center for Hepatitis B

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis B cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis B:
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Hepatitis B:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: hepatitis b

Sources

Genetic Tests for Hepatitis B

About this section
Sources

Anatomical Context for Hepatitis B

About this section

MalaCards organs/tissues related to Hepatitis B:

42
Liver, T Cells, Testes, Kidney, Bone, B Cells, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis B:

20
Liver
Sources

Publications for Hepatitis B

About this section

Articles related to Hepatitis B:

(show top 50) (show all 10974)
# Title Authors Year
1
Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients. ( 30315682 )
2019
2
Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure. ( 30827414 )
2019
3
Successful Treatment of a South African Pediatric Case of Acute Liver Failure Caused by Perinatal Transmission of Hepatitis B. ( 29601455 )
2019
4
Coexistence of localized tracheobronchial amyloidosis and chronic hepatitis B infection. ( 30688286 )
2019
5
Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. ( 30325778 )
2019
6
An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis. ( 30733983 )
2019
7
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. ( 30630365 )
2019
8
Vaccination for hepatitis B virus in an Australian pre-biologic population with rheumatoid arthritis. ( 30418119 )
2019
9
Reply to: Vaccination for hepatitis B virus in an Australian pre-biologic population with rheumatoid arthritis. ( 30418127 )
2019
10
Adequacy of scoring systems in diagnosing paediatric autoimmune hepatitis: retrospective study using a control group children with Hepatitis B infection. ( 30703247 )
2019
11
Diagnostic and prognostic value of mRNA expression of phospholipase C β family genes in hepatitis B virus‑associated hepatocellular carcinoma. ( 30896816 )
2019
12
Stabilization of E2-EPF UCP protein is implicated in hepatitis B virus-associated hepatocellular carcinoma progression. ( 30903204 )
2019
13
Autophagy-Related 5 Gene rs510432 Polymorphism Is Associated with Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. ( 30907204 )
2019
14
Identification of Potential Key Genes for Hepatitis B Virus-Associated Hepatocellular Carcinoma by Bioinformatics Analysis. ( 30864827 )
2019
15
Editorial: can hepatitis B core-related antigen be the new biomarker for hepatocellular carcinoma in nucleoside analogue-treated chronic hepatitis B? Author's reply. ( 30868631 )
2019
16
Editorial: can hepatitis B core-related antigen be the new biomarker for hepatocellular carcinoma in nucleoside analogue-treated chronic hepatitis B? ( 30868636 )
2019
17
Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma. ( 30870221 )
2019
18
Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. ( 30882847 )
2019
19
Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis B. ( 30882884 )
2019
20
Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. ( 30889843 )
2019
21
Comment on: Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma. ( 30840257 )
2019
22
On identification of agonistic interaction: Hepatitis B and C interaction on hepatocellular carcinoma. ( 30843247 )
2019
23
MicroRNA-325-3p inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma by down-regulation of aquaporin 5. ( 30805015 )
2019
24
Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma. ( 30815819 )
2019
25
Precancer antiviral treatment reduces microvascular invasion of early-stage Hepatitis B-related hepatocellular carcinoma. ( 30778112 )
2019
26
Myeloid-derived suppressor cells in the patients with liver resection for hepatitis B virus-related hepatocellular carcinoma. ( 30783140 )
2019
27
Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. ( 30786068 )
2019
28
The pretreatment platelet count is an independent predictor of tumor progression in patients undergoing transcatheter arterial chemoembolization with hepatitis B virus-related hepatocellular carcinoma. ( 30714399 )
2019
29
The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection. ( 30732177 )
2019
30
Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: a population-based cohort study. ( 30739359 )
2019
31
Interleukin-21 receptor gene polymorphism is associated with hepatitis B virus-related hepatocellular carcinoma in Chinese patients. ( 30758075 )
2019
32
Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review. ( 30679924 )
2019
33
Effect of hepatitis B virus DNA replication level and anti-HBV therapy on microvascular invasion of hepatocellular carcinoma. ( 30679943 )
2019
34
Hepatitis B virus x protein accelerated the proliferation of hepatocellular carcinoma cell through lncRNA SNHG20/PTEN pathway. ( 30690477 )
2019
35
Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir. ( 30694912 )
2019
36
Integrated analysis of lncRNA-associated ceRNA network reveals potential biomarkers for the prognosis of hepatitis B virus-related hepatocellular carcinoma. ( 30697079 )
2019
37
Naturally Occurring Hepatitis B Virus Mutations Leading to Endoplasmic Reticulum Stress and Their Contribution to the Progression of Hepatocellular Carcinoma. ( 30704071 )
2019
38
Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. ( 30705719 )
2019
39
The C-Terminus of Hepatitis B Virus-encoded X Protein Is Required for Lapatinib Sensitivity in Hepatocellular Carcinoma Cells. ( 30711950 )
2019
40
Association and interaction between model for end-stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus-associated hepatocellular carcinoma and portal vein tumor thrombi. ( 30655746 )
2019
41
Plasma B-cell activating factor levels and polymorphisms in hepatitis B-related hepatocellular carcinoma: Clinical correlation and prognosis. ( 30660167 )
2019
42
Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. ( 30663078 )
2019
43
Nomograms in Hepatectomy Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. ( 30671793 )
2019
44
Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. ( 30675188 )
2019
45
Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues. ( 30630598 )
2019
46
Reply to: "Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues". ( 30635241 )
2019
47
Corrigendum to "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B" [J Hepatol 69 (2018) 278-285]. ( 30635242 )
2019
48
Hepatitis B and hepatocellular carcinoma recurrence after living donor liver transplantation: The role of the Milan criteria. ( 30644364 )
2019
49
Decreased liver stiffness by transient elastography indicates lower incidence of hepatocellular carcinoma in patients with chronic hepatitis B. ( 30653099 )
2019
50
High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs. ( 30608393 )
2019
Sources

Variations for Hepatitis B

About this section
Sources

Expression for Hepatitis B

About this section
Search GEO for disease gene expression data for Hepatitis B.
Sources

Pathways for Hepatitis B

About this section

Pathways related to Hepatitis B according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Toll-like Receptor Signaling Pathway 38 1
Show member pathways
 12.94 IFNA1 IFNA2 IFNAR2 IFNG MBL2 TNF
2
Human cytomegalovirus infection 38
Show member pathways
 12.77 APOBEC3G IFNA1 IFNA2 IFNAR2 LAMTOR5 TNF
3
Influenza A 38
Show member pathways
 12.42 IFNA1 IFNA2 IFNAR2 IFNG TNF
4
Interferon gamma signaling 67
Show member pathways
 12.35 IFNA1 IFNA2 IFNAR2 IFNG
5
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.21 IFNA1 IFNA2 IFNAR2 IFNG
6
Selenium Micronutrient Network 1
Show member pathways
 12.15 ALB F2 IFNG TNF
7
Type I Interferon Signaling Pathways 66
Show member pathways
 12.09 IFNA1 IFNA2 IFNAR2 IFNG
8
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.03 IFNA1 IFNA2 IFNAR2 IFNG TNF
9
Tuberculosis 38
11.96 IFNA1 IFNA2 IFNG TNF
10
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 11.86 IFNA1 IFNA2 IFNAR2 IFNG TNF
11
Dendritic Cells Developmental Lineage Pathway 66
11.57 IFNA2 IFNG TNF
12
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.42 IFNAR2 IFNG TNF
13
Necroptosis 38
Show member pathways
 11.26 IFNA1 IFNA2 IFNAR2 IFNG TNF
14
Aryl Hydrocarbon Receptor Pathway 1
11.23 AIP IFNG TNF
15
Jak-Stat Signaling Pathway (sino) 68
11.2 IFNA1 IFNA2 IFNAR2 IFNG
16
FOXA2 and FOXA3 transcription factor networks 1
11.14 AFP ALB F2
Sources

GO Terms for Hepatitis B

About this section

Cellular components related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 AFP ALB F2 IFNA1 IFNA2 IFNAR2
2 extracellular space GO:0005615 9.44 AFP ALB CPD F2 GPT IFNA1

Biological processes related to Hepatitis B according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.95 F2 IFNA1 IFNA2 IFNG TNF
2 cytokine-mediated signaling pathway GO:0019221 9.89 IFNA1 IFNA2 IFNAR2 TNF
3 cell surface receptor signaling pathway GO:0007166 9.88 F2 IFNA2 IFNAR2 IFNG
4 positive regulation of protein phosphorylation GO:0001934 9.81 F2 IFNG MIR21 TNF
5 negative regulation of gene expression GO:0010629 9.77 IFNA2 IFNG MIR17 MIR21 TNF
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.74 F2 MIR21 TNF
7 type I interferon signaling pathway GO:0060337 9.71 IFNA1 IFNA2 IFNAR2
8 response to virus GO:0009615 9.71 IFNAR2 IFNG LAMTOR5 TNF
9 positive regulation of phagocytosis GO:0050766 9.63 MBL2 MIR17 TNF
10 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.61 MIR17 MIR21
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.6 IFNG TNF
12 negative regulation of growth of symbiont in host GO:0044130 9.58 MBL2 TNF
13 positive regulation of metalloendopeptidase activity GO:1904685 9.56 MIR17 MIR21
14 defense response to virus GO:0051607 9.55 APOBEC3G IFNA1 IFNA2 IFNAR2 IFNG
15 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.52 MIR17 MIR21
16 negative regulation of viral process GO:0048525 9.49 APOBEC3G MBL2
17 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.48 MIR21 TNF
18 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 IFNG TNF
19 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.43 IFNA1 IFNA2 IFNG
20 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 IFNG TNF
21 humoral immune response GO:0006959 9.26 IFNA1 IFNA2 IFNG TNF
22 positive regulation of vascular smooth muscle cell proliferation GO:1904707 8.92 MIR17 MIR21 MIR301A TNF

Molecular functions related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 type I interferon receptor binding GO:0005132 8.96 IFNA1 IFNA2
2 cytokine activity GO:0005125 8.92 IFNA1 IFNA2 IFNG TNF
Sources

Sources for Hepatitis B

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB